Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Figure 5
Effect of lenvatinib on the phosphorylation of RET with an activating mutation or a rearrangement in vitro. (a) Western blot analyses of the phosphorylation of RET in human medullary thyroid TT cells. TT cells were seeded and cultured overnight. They were then treated with lenvatinib at the indicated concentrations for 1 h before being lysed. (b) Western blot analyses of the phosphorylation of KIF5B-RET fusion proteins in normal thyroid cells; Nthy-ori 3-1 transfectants overexpressing KIF5B-RET (wild-type) or KIF5B-RET (M918T). Nthy-ori 3-1 transfectants were cultured overnight and then treated with lenvatinib at the indicated concentrations for 1 h before being lysed. Western blot analyses of the phosphorylation of RET and its downstream effectors in Nthy-ori 3-1 transfectants were then performed and representative images were shown.
